Sequoia Capital invests INR 100 Cr in GVK Pharma
November 27, 2007 | In: Uncategorized
GVK Biosciences Private Limited (GVK BIO), a Pharma & Biotech research and development outsourcing company, today announced that Sequoia Capital a leading global private investment firm has invested Rs.100 crores in GVK BIO.
GVK BIO started operations in 2001 at Hyderabad and has established itself as a leading Contract Research Organization in India. Currently GVK BIO is the only Indian CRO that provides an integrated service platform ranging from Informatics, MedChem and Biology services in Discovery research to Clinical Research and Data Management services on the Development side and further to Process Research and Custom Synthesis.
GVK Bio was G.V.K. Sanjav Reddy in 2001, while Dr D.S.Brar joined GVK Bio as promoter chairman in 2004. Previously Dr Brar played a significant role in building Ranbaxy (India’s largest Pharma Company) into a globally recognized Generics company with a pipeline of specialty and innovator (NCE) drugs. Dr. Brar is also involved with several international Pharma/Life-sciences companies in consulting/advisory role through Davix Management Services Pvt. Ltd
GVK BIO intends to use these funds to expand capacity in Drug Discovery services, build a state-of-the-art Campus at Hyderabad on a 25 acre site. provide new service offerings in Pre-clinical and Clinical space, and pursue growth opportunities through mergers and acquisitions.
Sequoia Capital has nominated Mr. Sandeep Singhal to the Board of GVK BIO.
Dimensions Consulting of Gurgaon were the advisors to GVK BIO for the transaction.